BURDEN, RISK FACTORS AND PREVENTION OF RESPIRATORY INFECTIONS AND INFECTIOUS DISEASES IN CHILDREN
Associate Professor Hannah Moore OAM
Program Head, Infection and Vaccines,
The Kids Research Institute Australia &
Associate Professor at the School of Population Health, Curtin University
Western Australia
RESEARCHER PROFILE (Filmed in Perth, Western Australia | December 2024)
A/Prof Hannah Moore OAM is an infectious disease epidemiologist; Co-Head of the Infectious Disease Epidemiology team within the Wesfarmers Centre of Vaccines and Infectious Diseases at The Kids Research Institute Australia and Associate Professor at the School of Population Health, Curtin University in Western Australia.
Her passion for research involves using population-based data to investigate how to recognise, prevent and reduce serious respiratory and other infectious diseases in children through estimating burden of disease and evaluating the effectiveness of vaccination programs. She has developed expertise in the epidemiology of Respiratory Syncytial Virus (RSV) in young children, where her research was pivotal in WA Governments’ decision to establish the first and most comprehensive RSV infant immunisation program in the nation. Raising awareness of RSV, understanding community burden and evaluating the impact of prevention measures is now a major focus of her research program. She has previously contributed to state and national influenza vaccination policy.
In 2020 A/Prof Moore joined the Strep A Vaccine Global Consortium (SAVAC) to increase knowledge and awareness of the global burden of Group A Streptococcal diseases. She now holds an activity lead position in the US$11M-funded SAVAC 2.0.
A/Prof Moore has been awarded more than $19M in competitive research grants, co-authored more than 140 papers, was TEDxPerth 2018 speaker, recipient of a WA Young Tall Poppy Award (2013) and the WA Premiers Science Early Career Scientist Award (2015). In 2024, she was honoured with a Medal of the Order of Australia for her service to epidemiology as a researcher.
Editor’s note: At the time of recording in September 2024, A/Prof Hannah Moore makes reference to needing a national RSV immunisation program. Efforts by her and others in campaigning were successful and in November 2024 the Australian National Immunisation Program was updated to include RSV from 2025. https://www.health.gov.au/news/national-immunisation-program-update-rsv-vaccine#:~:text=The%20inclusion%20of%20the%20RSV,announced%20as%20soon%20as%20possible.
https://orcid.org/0000-0003-4920-9991
-
Impact of Leukaemia Foundation’s Research Funding into Blood Cancer
Bill Stavreski is the Head of Research at the Leukaemia Foundation who talks about the research impact in recent years. The Foundation itself marks its 25th anniversary in 2025, having funded a wide range of health and medical research since 2000. With a focus on basic science, health services research, treatment, and care, the organisation has invested nearly $90 million (adjusted in current dollars terms) in approximately 370 research grants over the years.
-
Good and bad extracellular vesicles in health and disease
Associate Professor Joy Wolfram has joint appointments in the School of Chemical Engineering and the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland, and through her work at the AIBN, she aims to develop a new paradigm of therapeutics (using nanotechnology and cell products) to treat life-threatening diseases that are major causes of death globally, including cardiovascular disease, kidney disease, and breast cancer.
-
Funding the best brains to beat brain cancer
The Charlie Teo Foundation is dedicated to funding and advancing research into brain cancer, with a particular focus on developing more effective treatments and finding a cure for this devastating disease.
Since its inception, the foundation has committed nearly $15 million to brain cancer research, funding notable projects in Australia and the United States. These projects explore innovative approaches to understand and treat brain cancer more effectively, with a focus on translating findings from animal studies to human applications. Charlie’s dedication to finding solutions for this devastating disease remains unwavering as he travels frequently to collaborate with global researchers.
